▟ Vinebot intrinsic value, daily

← back

AMGN Amgen

pharma · valued with opus medium conviction · deep-dived 2026-11-06

HOLD
Intrinsic value$256.99
Price (at call)$460.28
Margin of safety -44.2%
vs market (rating basis) -13.7%

Durable biologics cash machine fairly priced on its base business; obesity is the swing factor.

The story

Amgen is a scaled biologics franchise. Steady volume growth in Repatha, Evenity, Tezspire and the Horizon rare-disease portfolio offsets biosimilar erosion of legacy drugs such as Prolia/Xgeva and Enbrel. MariTide gives it an obesity option, but that remains unproven, and the market price already gives it meaningful credit. The company is in mature mid-life: cash generation is strong, leverage from the Horizon acquisition is high, and its moat comes from biologics manufacturing scale and specialty commercial reach rather than any single patent.

TTM revenue grew about 6% and the operating margin reached 35.2%, so growth and margin move up modestly to match what was actually reported. I raised sales-to-capital from 0.7 to 0.9 (a material move). The reported 0.61 is depressed by Horizon goodwill. Incremental growth is funded by R&D and modest capex, not acquisitions. My prior 199 value implied a >100% gap with a widely covered stock, which signaled over-penalized reinvestment.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth2.5%
Forecast horizon8y
Target operating margin35.0%
Years to target margin3
Sales-to-capital0.90
Beta0.85
Failure probability1.0%
Cost of capital (WACC)8.2%
Terminal WACC8.8%

Valuation bridge

PV of explicit FCFF68.89B
PV of terminal value117.00B
Equity value139.01B
÷ shares → per share$256.99

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 41.24B 6.0% 35.1% 12.44B 2.59B 9.85B 9.10B
2 43.51B 5.5% 35.1% 13.10B 2.52B 10.58B 9.03B
3 45.68B 5.0% 35.0% 13.73B 2.42B 11.32B 8.92B
4 47.74B 4.5% 35.0% 14.35B 2.28B 12.07B 8.79B
5 49.65B 4.0% 35.0% 14.93B 2.12B 12.81B 8.62B
6 51.38B 3.5% 35.0% 15.45B 1.93B 13.52B 8.40B
7 52.92B 3.0% 35.0% 15.91B 1.71B 14.20B 8.15B
8 54.25B 2.5% 35.0% 16.31B 1.47B 14.84B 7.87B

Key risks

  • MariTide efficacy, tolerability or dosing disappoints against entrenched GLP-1 incumbents
  • Biosimilar erosion of Prolia/Xgeva and Enbrel runs faster than new-product growth can offset
  • IRA Medicare price negotiation and MFN-style pricing pressure compress US margins

Catalysts

  • MariTide Phase 3 readouts and the design of its maintenance-dosing strategy
  • Continued deleveraging of Horizon debt, lifting equity value per share

History

DatePriceIntrinsicMoSRating
2026-11-06$460.28 $256.99 -44.2% HOLD
2026-10-05$403.04 $199.31 -50.5% HOLD
2026-09-01$429.88 $386.01 -10.2% STRONG BUY
2026-07-30$387.64 $202.22 -47.8% HOLD
2026-06-26$352.82 $231.95 -34.3% BUY
2026-06-23$347.01 $201.96 -41.8% BUY